Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Adjusting Europe's drug regulation to public health needs.

× No keyword cloud information.

12 in total

Review 1. Education and debate: Making regulation responsive to commercial interests: streamlining drug industry watchdogs.

Authors: John Abraham; Danielle Bardelay; Christophe Kopp; J D Kleinke; Emma Bennion
Journal: BMJ Date: 2002-11-16

2. Varying and "atypical" indications for atypical antipsychotics.

Authors: Corrado Barbui; Michele Tansella; Silvio Garattini
Journal: Psychopharmacology (Berl) Date: 2003-05-22 Impact factor: 4.530

3. Efficacy, safety, and cost of new anticancer drugs.

Authors: Silvio Garattini; Vittorio Bertele
Journal: BMJ Date: 2002-08-03

4. CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation?

Authors: Corrado Barbui; Andrea Cipriani; Camilla Lintas; Vittorio Bertelé; Silvio Garattini
Journal: Psychopharmacology (Berl) Date: 2006-11-22 Impact factor: 4.530

Review 5. How can we regulate medicines better?

Authors: Silvio Garattini; Vittorio Bertele'
Journal: BMJ Date: 2007-10-20

6. Direct to consumer advertising of drugs in Europe.

Authors: Nicola Magrini; Maria Font
Journal: BMJ Date: 2007-09-15

7. The politics and bio-ethics of regulatory trust: case-studies of pharmaceuticals.

Authors: John Abraham
Journal: Med Health Care Philos Date: 2008-07-22

8. Does the development of new medicinal products in the European Union address global and regional health concerns?

Authors: Ferrán Catalá-López; Anna García-Altés; Elena Alvarez-Martín; Ricard Gènova-Maleras; Consuelo Morant-Ginestar
Journal: Popul Health Metr Date: 2010-12-20

9. Clinical and outcome research in oncology. The need for integration.

Authors: Giovanni Apolone
Journal: Health Qual Life Outcomes Date: 2003-04-03 Impact factor: 3.186

10. Equivalence and noninferiority trials - are they viable alternatives for registration of new drugs? (III).

Authors: Cornel Pater
Journal: Curr Control Trials Cardiovasc Med Date: 2004-08-17